Th1/Th2 cytokine balance in arthritis by Miossec, P. & Berg, W. van den
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24983
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
A R TH R ITIS  & RHEUM ATISM
Vol. 40, No. 12, December 1997, pp 2105-2115
© 1997, American College of Rheumatology 2105
REVIEW
Thl/Th2 CYTOKINE BALANCE IN ARTHRITIS
PIERRE MIOSSEC and WIM v a n  d e n  BERG
Studies of the contribution of cytokines to the 
pathogenesis of rheumatoid arthritis (RA) have focused 
largely on monocyte-derived proinflammatory cytokines 
(1). Interleukin-1 (IL-1) and tumor necrosis factor a  
(TNFa), characterized as the most important ones, have 
been selected as significant therapeutic targets (2). The 
contribution of T cells to RA has been more a matter of 
debate and has been addressed in a number of reviews 
published in Arthritis & Rheumatism (3-5). A major issue 
has been—and remains—the remarkable contrast be­
tween the presence of a T cell infiltrate and the relative 
failure to detect definite markers of activity of these 
cells. Indeed, the low level of expression and production 
by the rheumatoid synovium of T cell-derived cyto­
kines, as first described for IL-2 and interferon-y 
(IFNy), then extended to TNF/3 and IL-4, were a 
primary reason to question the direct contribution of 
T cells to this disease (6).
The field has advanced recently by the descrip­
tion of new T cell-derived cytokines, which were as­
signed to various subsets of T cells. These subsets have, 
in turn, been associated with the development of differ­
ent patterns of disease in mice and humans. Finally, 
modulation of the cytokine profile is now considered a 
therapeutic mean (7). In diseases such as RA, where a 
specific causative agent and/or antigen has not been 
identified, bypassing the antigen and acting on 
cytokine balance might 
autoimmunity and chronic inflammation (8,9).
a way to control
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Thl/Th2 cytokine balance from mice to humans
In 1986, Mosmann and Coffman showed that 
mouse CD4+ T cell clones could be classified into 
distinct subsets according to their cytokine production 
pattern (10). Those studies established that IL-2 and 
IFNy were produced by Thl clones, whereas IL-4 and 
IL-5 were mostly produced by Th2 clones. Later, new 
cytokines were identified and were classified as T hl for 
TNF/3 and as Th2 for IL-6, IL-10, and IL-13. Simulta­
neously, a precursor (ThO) subset that produced IL-4, 
IL-2, and IFNy was described (11). These precursor cells 
are themselves derived from virgin T cells (Thp), which 
secrete IL-2 following activation.
According to this simple dichotomy, Thl cyto­
kines favor T cell-mediated cellular immunity and cy­
totoxicity, delayed-type hypersensitivity (DTH), and 
they activate monocytes, which leads to the production 
of proinflammatory cytokines. Th2 cytokines favor B cell 
mediated-humoral immunity, induce 
with IL-4 and IL-13, activate eosinophils with IL-5, and 
deactivate monocytes, which leads to an antiinflamma­
tory cytokine pattern (Figure 1).
Next, it was important to demonstrate that these 
patterns could also be recognized at a polyclonal level 
when looking at their tissue expression and production. 
Indeed, observations in animal 
contribution of Thl cells to DTH and the contribution of 
Th2 cells to allergies and some parasitic infections. It 
was clear from the beginning that in the mouse models, 
the H2 genetic background had a major role in deter-
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The same dichotomy was later applied to human 
T cells, starting with T cell clones and 
application to various diseases (12,13). 
clones from RA synovium were found to pr 
amounts of IFNy, but not IL-4, which 
classification as Thl cells (14,15). A similar 
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Figure 1. The Thl/Th2 cytokine balance and biologic functions. A 
predominant T hl profile is implicated in T cell-mediated immunity, 
whereas a predominant Th2 profile is implicated in B cell-mediated 
immunity. The opposite effects on monocyte activation are the basis 
for the control of chronic inflammation. IL = interleukin; IFNy = 
interferon-y.
than T cells, represent a major source of IL-10 (19). The 
same conclusion was reached for IL-6, TNFa, and 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF). Thus, with regard to the relative amount of 
cytokine, IL-10 cannot be considered a major T cell- 
derived cytokine.
Recently, a Th3 subset has been defined for cells 
producing transforming growth factor /3 (TGF/3), which 
is largely a monocyte/mesenchymal cell-derived growth 
factor. Indeed, a monocyte cytokine balance parallels 
the T cell cytokine balance. Monocytes are the major 
source of IL-12, which acts on T cells and natural killer 
cells to induce the production of IFNy. This leads to a 
strong Thl pattern. Conversely, IL-10 produced by 
monocytes inhibits the production of IFNy, and thus 
counteracts the effect of IL-12 (7) (Figure 3).
Cytokine specificity inside the balance. Cytokines 
such as IL-4 and IL-10 have been classified as Th2 
cytokines. Although they share major functions, such as 
the inhibition of proinflammatory cytokine production 
by monocytes, they have opposite effects on many other 
targets. For instance, IL-10 appears to be a major factor 
for inducing complete plasma cell differentiation when 
B cells are in contact with synoviocytes, an effect which 
is inhibited by IL-4 (20). Similarly, differences have been
sclerosis. These diseases were then classified as Thl 
conditions (Figure 2).
Conversely, with respect to allergies, CD4+ T 
cells infiltrating the conjunctiva of patients with vernal
conjunctivitis or allergen-specific T cell clones obtained 
from patients with atopy were essentially of the Th2 type 
(16). The contribution of IL-4 to scleroderma and of 
IL-10 to lupus led to the classification of these diseases 
as Th2 conditions (17).
Extension of the Thl/Th2 cytokine balance
Production by other cell subsets. Further studies 
in mice and in humans showed that T cell clones could in 
fact produce a mixture of cytokines. In the case of 
arthritis, a large proportion of the heat-shock protein- 
specific a//3 CD4+ clones, which produce large amounts 
of IFNy, also released significant amounts of IL-10 (15). 
Moreover, some of these cytokines were produced by 
cells other than Th cells, such as CD8+ cytotoxic T cells, 
y/8 T cells, and even cells other than T cells (18). IL-4 is 
also produced by mast cells, basophils, and eosinophils. 
Human IL-10 is produced by monocytes and B cells, as 
well as by Thl cells. In RA synovium, monocytes, rather
Heat-shock proteins 
Borrella
INDUCTION
IL-2 IFN y
T
i A
I L
INHIBITION
I
Lyme arthritis
Rheumatoid arthritis
Thyroiditis
Diabetes
Multiple sclerosis
Allergens
HIV
INDUCTION
IL-4 IL-13 IL-10 IL-5
Allergic diseases
Asthma
Scleroderma
SLE
HIV infection 
Pregnancy
Figure 2. The Thl/Th2 cytokine balance and diseases. A predominant 
Thl profile has been associated with rheumatoid arthritis, Lyme 
arthritis, multiple sclerosis, diabetes, and thyroiditis. A Th2 profile, 
with the predominant contribution of interleukin-4 (IL-4) and IL-5, 
has been associated with allergic diseases and scleroderma. The 
predominant contribution of IL-10 has been suggested in pregnancy, 
systemic lupus erythematosus (SLE), and early human immunodefi­
ciency virus (HIV) infection. IFN y =  interferon-y.
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Figure 3. Control of the Thl/T h2 cytokine balance by monocyte- 
derived regulatory cytokines. Interleukin-12 (IL-12) is the critical 
monocyte-derived cytokine that induces interferon-7  (IFNy) produc­
tion and a T h l profile through the activation of Stat-4. IL-4 is the 
critical cytokine that induces a Th2 profile through the activation of 
Stat-6. Solid lines represent stimulatory effects; broken lines represent 
inhibitory effects.
revealed when comparing the responses of monocytes 
from blood or synovium with these cytokines (21).
IL-4 and IL-13 share most of their activities, 
particularly their antiinflammatory properties (22). 
However, the effect of IL-4 on T cells appears more 
potent than that of IL-13. Furthermore, the 2 cytokines 
use the same multichain receptor, but in a competitive 
manner, as shown particularly with activated synovio­
cytes (23). The reason for the presence of the 2 mole­
cules is unclear, and the use of one or thé other cytokine 
for treatment would be difficult to justify.
New members of the Thl/Th2 cytokine balance. 
New cytokines have been isolated, and their classifica­
tion is still pending. Among them, IL-17 is of particular 
interest in inflammation. This cytokine, which is pro­
duced by CD4+ T cells, acts on mesenchymal cells, such 
as synoviocytes, to induce the production of a proinflam­
matory pattern (24), with the induction of IL-6, GM- 
CSF, and prostaglandin E2 production (25). 
results indicate that this can be extended to other 
factors, such as leukemia inhibitory factor (LIF). These 
characteristics indicate that IL-17 can be classified as a
Moreover on synovio-
cytes represents a new way for T cells to i 
mation, in particular, in association with low 
monocyte-derived cytokines.
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The Thl/Th2 cytokine balance in action
The dynamic pattern of the Thl/Th2 cytokine 
balance. The pattern of regulatory cytokine production 
is controlled by many parameters: the antigen structure 
(arthritogenic versus tolerogenic epitopes), the mode of
administration versus oral), the
presenting cells (dendritic cells versus B cells), and the 
cytokine and steroid environment (Thl versus Th2) (26). 
This ability to switch between patterns may be useful
se concepts to treatment.
First, each Th cytokine subset induces its own 
production and favors the differentiation of naive T cells 
into the same subset. Thus IFNy induces its own produc­
tion and Thl cell activation, whereas IL-4 activates Th2.
The second important feature of Thl and Th2
cells is the ability of one subset to regulate the activities 
of the other. Both IL-4 and IL-10 are strong inhibitors of 
IFNy production, and IFNy inhibits IL-10 production 
(27) (Figure 1). Early results showed the direct contri­
bution of the antigen. T cells from a given normal 
individual produce Thl cytokines in response to myco­
bacterial antigens and Th2 cytokines in response to 
allergens (13). Furthermore, culture of normal T cells in 
the presence of either IFNy or IL-4 results in the 
development of clones of either Thl or Th2 
respectively (28).
Recent results have shown that the balance can 
be manipulated with mitogens 
level of a specific antigen. This is a critical issue when 
considering the treatment of diseases of unknown spe­
cific origin, such as RA. These studies have indies 
ways to induce a switch between the 2 
Human umbilical cord blood naive T cells activated 
mitogens can be directed toward Thl when cultured in 
the presence of IL-12 and anti-IL-4, and toward Th2 
when cultured in the presence of IL-4 and anti-IL-12 
(29).
IL-12 and that of IL-4 in the switch to Thl and Th2, 
respectively (Figure 3).
critical role of
ays activated by
have focused on the role of the Stat transcription factors. 
IL-12 acts through the activation of Stat-4. Indeed, the 
inactivation of the Stat-4 gene in mice leads to a defect 
in IL-12 production, and thus of Thl functions, com­
bined with an increase in Th2 functions (30). Conversely, 
Stat-6 is critical for IL-4-and Th2-mediated events, as 
shown with Stat-6 knockout mice (31,32).
To monitor these changes, various surface mark­
ers, such as CD27 and CD30, have been proposed to
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specifically identify these populations. However, addi­
tional studies have put to question their value for 
differentiating these subsets. Regarding arthritis, blood
CD4,CD45RBdim,CD27 — T cells have been character­
ized as the IL-4-producing subset (33). Their presence 
in the joint may represent an attempt to control inflam­
mation (34). Recent studies have indicated a good 
correlation between the Thl pattern and the expression 
of the 02 chain of the IL-12 receptor (29). Indeed IL-12 
is critical for differentiation into a Thl phenotype. 
Similarly, the transcription factor GATA-3 has been 
shown to be necessary and sufficient for Th2 pattern 
expression in mouse T cells (35). Additional studies are 
needed to determine whether these markers will be 
useful in the context of arthritis.
Molecules controlling the Thl/Th2 cytokine bal­
ance. Various molecules contribute to the control of 
Thl/Th2 development. The costimulatory molecules 
B7-1 (CD80) and B7-2 (CD86) expressed on antigen- 
presenting cells act as a second signal and control the 
differentiation of the 2 major subsets (36). Their ligands 
on T cells are CD28 and CTLA-4 (37). This second step 
of activation follows the first signal given by the inter­
action between the T cell receptor and the antigen major 
histocompatibility complex, which confers T cell speci­
ficity. CD28 costimulation was found to promote the 
production of Th2 cytokines by mouse T cells through an 
IL-4-dependent mechanism (38).
Initial results in the mouse have indicated that 
activation of the B7-1 pathway stimulates the Thl sub­
set, whereas B7-2 activation stimulates the Th2 subset. 
Conversely, blockade of B7-1 was able to control Thl- 
mediated diseases such as diabetes and encephalomyeli­
tis (39,40). However, results in other systems indicate 
that this represents an oversimplification (41).
Application to humans has proven to be more 
difficult. However, the contribution of IL-4 appears to 
be critical. B7-2 stimulation specifically controls IL-4 
production by naive T cells, whereas both B7-1 and B7-2 
can induce IL-4 production by memory T cells (42). In 
the absence of the regulatory properties of IL-4, T cells 
remain sensitive to other regulatory cytokines, such as 
IL-12, which induces a strong Thl profile by inducing 
IFNy production. In conclusion, the presence or absence 
of IL-4 appears to represent the critical control for the 
Thl/Th2 switch.
Thl/Th2 cytokine balance in arthritis
Expression in the synovium. This simple classifi­
cation has been more difficult to reconstitute when
looking at the cytokines produced by the synovium itself. 
Findings concerning the levels of these T cell-derived 
cytokines in RA have been contradictory and their 
specific detection difficult, despite infiltration of the 
synovium by many T cells (6,43). Although contradictory 
results have been published, the expression of IL-2 and 
IFNy messenger RNA (mRNA) by RA synovium was 
not detected in one study even with the use of the most 
recent and sensitive methods (44). IL-4 protein and 
mRNA could not be detected in synovial fluid, synovial 
supernatants, or the synovium itself (45).
Cytokines such as IFNy and IL-10 could not be 
easily detected in the supernatants of synovium pieces
and(19). However, staining for IL-10 was 
endogenous IL-10 was shown to be active, since an 
increased production of proinflammatory cytokines was 
observed in the presence of an inhibitory anti-IL-10 
antibody (46). As indicated above, isolated synovial T 
cells do produce significant levels of IFNy. Such produc­
tion may be sufficient to induce potent local effects 
(Figure 4). The inhibitory effect of these 2 cytokines on 
each other may explain the absence of secretion when 
the secreting cells are in close contact (27), but the 
inhibitory component remains insufficient to control 
disease activity. Similar conclusions apply to TGF/3, 
which are also largely present in an active form in
RA (45).
Thl/Th2 cytokine balance and the search for the 
cause ofRA. A large body of work has tried to isolate the 
specific antigen(s) that contributes to RA. The lack of an 
identified causative agent in autoimmune diseases re­
mains the major limitation to early diagnosis and treat­
ment. In Lyme arthritis, the bacterial antigen is well 
known, and the histologic appearance of the synovium is 
very similar to that seen in RA. T cell clones specific for
the bacterial were shown to
amounts of IFNy with no IL-4, as in RA (47). Similarly,
have i n md
leprosy (48,49), Along the same line, T cells infected by
retrovirus human T opic virus I
(HTLV-I) tend to produce an extended cytokine profile, 
combining T cell-derived cytokines of the type 1 pattern 
and monocyte-type cytokines. Such a profile could con­
tribute to the rheumatoid-like clinical presentation ob­
served both in humans and in transgenic mice for the 
Tax regulatory protein from HTLV-I (50).
Regarding the failure to detect a precise cause of 
RA, recent studies with a new transgenic model have 
indicated that destructive arthritis can be present in the 
absence of an intraarticular antigen (51). Whatever the
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Figure 4. Multiple sites of action of Th2 cytokines. Production of interleukin-4 (IL-4) is provided 
by Th2 cells, whereas both Th2 cells and macrophages (Macr) contribute to IL-10 and transforming 
growth factor 0 (TGFb) levels. These regulatory cytokines will interfere with the Thl/Th2 balance, 
but a major effect will be related to inhibition of tumor necrosis factor (TNF)/IL-1 production. 
Moreover, direct effects on chondrocytes (Chondr) as well as osteoclasts (Osteoc)/osteoblasts 
(Osteob) in the bone should be taken into account. APC = antigen-presenting cell; IFN-g = 
interferon-7 ; Fibro = fibroblasts.
conclusion, direct action on the cytokine balance repre­
sents a way to bypass the initiating event.
Thl/Th2 cytokine balance and the chronicity of 
RA. Increased migration of a large polyclonal population 
of T cell specificity results in the formation of the 
inflammatory lesion. Endothelial cell swelling, leading 
to the formation of high endothelial venules, is one of 
the earliest pathologic findings. These changes are asso­
ciated with increased expression of adhesion molecules, 
leading to increased cell migration. Migration of Thl 
cells, rather than Th2 cells, is facilitated through the use 
of the E and P selectins (52). Thus, expression of such 
adhesion molecules is mandatory for an increase in the 
migration of T cells in a non-antigen-specific manner. 
These findings in various animal models suggest that it is 
of therapeutic interest to act on the migration of inflam­
matory cells. Indeed, targeting of intercellular adhesion 
molecule 1 has been applied in the treatment of RA 
(53). To further refine such a concept, a more specific 
approach would be to block the migration of disease- 
inducing Thl cells and favor that of the protective Th2
cells (54).
These changes in migration pattern are associ­
ated with differences between systemic and synovial 
sites. During chronic inflammation, migration of proin- 
flammatory cells is increased, whereas that of protective
cells is defective, leading to their relative accumulation 
in the bloodstream (52). In blood from RA patients, 
defects in IFNy production have been reported (55). 
Results with very sensitive IL-4 assays indicated that
activated RA whole blood cells produced more IL-4 
than did controls, and with a higher IL-4:IFNy ratio. 
Such findings are consistent with the increased produc­
tion in blood as well as in activated peripheral blood 
mononuclear cell supernatants of soluble CD23, the 
production of which is enhanced by IL-4 (56). 
results are in contrast to those found in the RA syno­
vium, where a Thl pattern is predominant.
Thl/Th2 cytokine balance as a therapeutic 
animal models
in
Direct targeting of cytokines. Results in various 
models have indicated that control 
tory diseases can be achieved in the absence of a direct 
action on the antigen. The regulatory role of IL-4 and 
IL-10 has been convincingly demonstrated in most, but 
not all, animal models of arthritis (57) (Figure 4). IL-10 
production is found in the synovial tissue of DBA/1 mice 
shortly after the onset of autoimmune collagen arthritis, 
and animals receiving neutralizing anti-IL-10 antibodies 
display an accelerated disease onset and more severe
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arthritis (58,59). Anti-IL-4 treatment around the time of 
the spontaneous onset of arthritis did not provoke 
enhanced severity (59), underlining a more dominant 
role of IL-10 in endogenous control, which is consistent 
with low levels of IL-4 in the arthritic tissue. However, 
combined treatment with antibodies against both cyto­
kines resulted in the highest incidence and severity, 
indicating a significant contribution of IL-4 in disease 
control.
It is still unclear how much of the endogenous 
IL-10 is contributed to by Th2 lymphocytes. It seems 
likely that a large part of IL-10 in the arthritic synovial 
tissue is of macrophage origin. This may simultaneously 
explain the relative lack of IL-4 as compared with IL-10. 
Unlike IL-10, IL-4 is a selective product of T cells, with 
a minor contribution from local tissue mast cells. Con­
sistent with observations in arthritis, IL-10 exerts a 
similar controlling role in other diseases, such as auto­
immune encephalomyelitis, thyroiditis, and colitis (60). 
Besides IL-10, TGF/3 also provides disease control, as 
shown by signs of spontaneous colitis both in IL-10- and 
TGF/3-deficient mice (61,62). Likewise, TGF/3 may be 
derived from T  cells as well as from tissue macrophages.
Although rather high levels of IL-10 and TGF/3 
can be found in arthritic tissue, further suppression of 
arthritis can still be achieved by exogenous application. 
Progression of established collagen arthritis could be 
ameliorated by daily treatment with IL-10 (63), but 
better suppression was found after combination treat­
ment with IL-4 and IL-10. The mechanism of this
synergistic protection is linked to a more optimal sup­
pression of both TNFa and IL-1 production, and to a 
marked up-regulation of the IL-1 receptor antagonist 
(IL-lRa)/IL-l balance in synovium and cartilage (59). 
Moreover, there is evidence that IL-4 has a direct 
protective effect against chondrocyte-driven cartilage 
degradation (64).
Induction of endogenous protective cytokines.
Although the therapeutic efficacy of daily IL-4/IL-10 
treatment has now been proven in animal models of 
arthritis, it remains a challenge to avoid daily dosing and 
to find optimal ways to increase the endogenous produc­
tion of suppressive cytokines at the site or to suppress 
the continued generation and propagation of Thl cells. 
Strongly polarized T cell phenotypes are probably most 
relevant to chronic diseases that are characterized by 
continued antigen exposure, since it was found that 
reversibility of Thl and Th2 phenotypes was lost after 
prolonged in vitro antigen stimulation (65). Despite 
major efforts in sophisticated animal models using T cell 
lines or clones, our understanding of regulation in
conventionally immunized animals is still scant. More­
over, regulation seems rather different in early and late 
disease.
IL-12 is now recognized as a critical cytokine in 
the generation of Thl cells. It is produced in large 
quantities upon activation of macrophages with bacterial 
stimuli. IL-12 can replace bacteria in adjuvant prepara­
tions, and this cytokine may be the natural link between 
intercurrent infections and relapses of autoimmune dis­
eases. In murine collagen-induced arthritis, IL-12 mark­
edly enhanced disease expression and severity when 
given during immunization (66) or at the time of ex­
pected onset, whereas anti-IL-12 treatment prevented 
arthritis onset (67). However, in established arthritis, 
regulation by IL-12 seems more complex. Exacerbations 
were noted after late anti-IL-12 treatment, apparently 
linked to IL-12-mediated induction of IL-10 (67). The 
latter phenomenon may represent a natural feedback 
mechanism that controls for largely skewed, and there­
fore pathogenic, Thl responses. The bimodal activity of 
IL-12 will seriously complicate IL-12-directed therapy in 
arthritis.
Induction of bystander suppression. Of interest, 
activated Th2/Th3 cells may protect individuals from 
Thl-dependent arthritis through antigen-driven genera­
tion of IL-4, IL-10, or TGF/3. The principle of so-called 
bystander suppression through this set of cytokines 
provides a means of bypassing the lack of information on
particular autoantigens involved in the (68)
(Figure 5). Accepted ways to achieve Th2/Th3 responses 
are antigen dosing at mucosal surfaces, through the oral 
or nasal route, and stimulation with modified antigens 
(69,70). Oral dosing has a tendency to mainly generate 
Th3, TGF/3-dependent suppression. This was demon­
strated by a loss of protection after treatment with 
neutralizing anti-TGF/3 antibodies, whereas this path­
way was still functional in IL-4-deficient mice (71). In 
contrast, studies with modified 
dence for the existence of an IL-4 
and it seems likely that multiple mecnamsms may 
operational (72). Of interest, treatment with nondeplet­
ing anti-CD4 antibodies during early antigen exposure 
caused a shift from Thl to IL-4-producing Th2 cells 
(73), thus providing another means of manipulating 
T cell cytokine balance.
Although major research in this area has focused 
on understanding the immunoregulation mechanisms in 
autoimmune models such as encephalomyelitis and co­
litis (74), results in arthritis models have shown suppres­
sion of disease upon oral dosing with type II collagen 
(75,76). Although the principle of using an autoantigen
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Figure 5. Bystander suppression to regulate arthritis. This scheme depicts propagation of chronic 
arthritis by arthritogenic epitopes released from the articular cartilage, which then stimulate Thl 
cells in the synovial tissue. In principle, any cartilage epitope released from the articular cartilage 
during normal tissue turnover, or enhanced during arthritic processes, might be considered a joint- 
specific bystander stimulus, provided that we are able to enrich sufficient Th2 or Th3 cells with the 
desired epitope specificity at the site. These cells will then release suppressive mediators (interleukin-4 
[IL-4], transforming growth factor ¡3 [TGFb]) to control the arthritogenic Thl reaction. Likewise, 
endogenous proteins abundantly present under inflamed conditions in the synovial tissue, such as 
endogenous heat-shock proteins (hsp), may fulfill a similar role, if we are able to manipulate the T  cell 
reactivity to these molecules in the desired direction (68). Finally, exogenous antigens (Ag) can be 
artificially “planted” in the joint by local injection, in the context of proper Th2/ Th3 reactivity previously 
induced by preimmunization/tolerization against the selected antigen. The selectivity of such epitopes 
for Thl/Th2/Th3 cells will determine the net effect and safety.
from the articular cartilage of the joint to create local 
generation of protective bystander cytokines at the site 
seems an attractive approach, the major hurdle is the
Oral or nasal dosing will generate Th2/Th3 T cells
selectins (52), such Th2 cells may not end up in large 
quantities at the desired spot.
Acting on the Thl/Th2 cytokine balance to control RA
Effect of exogenous cytokines. Preclinical studies 
have been performed with synovium pieces and cell 
suspensions obtained after enzymatic digestion. Addi­
tion of exogenous IL-4, IL-13, and to a lesser extent, 
IL-10 to synovium pieces strongly reduced the produc­
tion of proinflammatory cytokines, whereas the produc-
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but it will be limited by the number of affected joints. 
Preliminary phase I trials have started in RA, using the 
systemic administration of IL-10 and IL-4.
Administration of cytokine by gene therapy has 
proven to be successful in animal models of arthritis 
(83), but the precise local control of such genes remains 
to be resolved. Another means could be the ex vivo 
stimulation of circulating lymphocytes with exogenous 
cytokines with reinjection of the cells. Such a procedure 
has already been used with IL-2 to obtain lymphokine- 
activated killer cells in the treatment of cancer. Ex vivo 
activation with Th2 cytokines can be a way to induce the 
differentiation of uncommitted or Thl cells into Th2 
cells.
Induction of the endogenous production of pro­
tective cytokines. Induction of a remission or cure of RA 
has been observed in a number of clinical conditions in 
the absence of an obvious action at the level of the cause 
(9). These conditions are important to consider, since it 
is tempting to attempt to reproduce such modulation for 
a longer period. The most obvious situation is the 
remission of RA that is observed during pregnancy and 
the flare that follows delivery. In this situation, T 
cell-mediated immunity—rejection of the fetus—must 
be down-regulated, whereas the fetus has to be pro­
tected with maternal IgG (84). These 2 components 
suggest the contribution of factors such as TGF/3 and 
IL-10. Indeed, high levels of expression of IL-10 at the 
placental interface have been observed in the mouse 
(85). More importantly, the improvement in RA appears 
to be directly related to the degree of maternal-fetal 
disparity, which leads to an increased need for fetal 
tolerance (86). Similar observations have been made for 
the side of slow-acting (87), for early
human immunodeficiency virus infection (88), and for 
allogeneic bone marrow transplantation (89) (Figure 2). 
These conditions appear to be associated with a Th2 
cytokine profile (8,90) (Figure 2).
Whatever the mechanism, such observations in­
dicate that even longstanding inflammatory disease can 
improve without antigen-specific intervention. The next 
logical step is to reproduce these situations in vitro and 
in vivo. Although the clinical data from the first small 
trials of type II collagen dosing in RA patients looked 
promising (91), more extended studies did not confirm 
efficacy (92), and we are yet at the beginning of explor­
ing focused manipulation of local Thl/Th2/Th3 bal­
ances. Nevertheless, induction of bystander suppression 
by oral tolerance could represent a simple way to control 
inflammation.
It should be kept in mind that excessive Th2
switching may be harmful. Excesses of IL-4 and IL-13 
could lead to allergy and asthma. An excess of IL-10 
could favor B cell/plasma cell activation with increased 
autoantibody production. Such events may contribute to 
some extraarticular manifestations such as rheumatoid 
vasculitis or lymphomas that are seen during the course 
of RA.
Conclusion
The concept of cytokine balance in arthritis is 
appealing since it leads to treatment even if the cause of
the "ase cannot be identified. This implies early 
treatment before destruction in patients at high risk. The 
genetic and hormonal backgrounds are obviously linked 
to RA severity. Recent findings suggest that the invasive 
pattern of RA synoviocytes is associated with, and may 
be the consequence of, irreversible somatic mutations 
(93). If this is the case, then endogenous control of such 
proliferation may remain limited when the disease be­
comes chronic. Taken together, these factors strongly 
point to the need for better early diagnosis and prog­
nostic markers to ensure early treatment. In this situa­
tion, acting on the endogenous regulatory cytokine 
balance may represent a more natural way to prevent the 
consequences of chronic inflammation.
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